> That should be relatively easy to do for the mRNA vaccines That isn't super obvious to me anymore, after it was pointed out to me that the current mRNA vacci

> That should be relatively easy to do for the mRNA vaccines That isn't super obvious to me anymore, after it was pointed out to me that the current mRNA vaccines rely on a modified sequence for the spike protein, designed to make the protein stable enough to be usable in the vaccine process (described here [1] as "antigen S-2P" - "S" for "Spike" and "2P" for the two proline substitutions in the sequence). It's my understanding that this work dates to 2017 [2], and that it might not be quick or easy to replicate for new spike protein variants. [1] https://www.nature.com/articles/s41577-020-00480-0 https://www.nature.com/articles/s41577-020-00480-0 [2] Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. USA 114, E7348–E7357 (2017).